News & Updates

Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company

04/01/2022

Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by Lightspeed Venture Partners. The company licensed its lead compound, KRLS-017, from Ube Industries, Ltd., a premier Japanese chemical manufacturer. The company also completed…

Read More

Dubai on the Brain: NeuroVigil’s Philip Low Assembles Dream Team to Launch Modern Neurotechnology Industry; Expands Conglomerate in Montreal, Canada

04/01/2022

Senior leaders in science, government, and industry recruited for international “Manhattan Project for the Brain” Excerpt from the Press Release: DUBAI, United Arab Emirates & PALO ALTO, Calif. & MONTREAL–(BUSINESS WIRE)–Neurotechnology Powerhouse NeuroVigil (ranked “Top 10 most innovative companies in health care” by Washington Post and Fast Company) announced at the New Technology & Mental…

Read More

New Study Shows Virtual Bronchoscopic Navigation With Fused Fluoroscopy and Vessel Mapping Using Broncus Archimedes System is Safe and Effective in Obtaining High Biopsy Yield in Lung Tumors

03/31/2022

Excerpt from the Press Release: SAN JOSE, Calif.–(BUSINESS WIRE)–Broncus Medical (02216HK), Inc., developer of diagnostic and therapeutic technology for a variety of lung diseases, today announced online publication in the Respirology journal of a global, multicenter study demonstrating the effectiveness of the company’s Archimedes® Virtual Bronchoscopic Navigation (VBN) System in guiding the sampling of peripheral…

Read More

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

03/31/2022

CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as…

Read More

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

03/31/2022

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery. Excerpt from the Press Release: MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative…

Read More

BioFluidica Extends NIH Award through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19

03/30/2022

BioFluidica LiquidScan Next-Generation Testing Platform, Can Detect Diseases in 15 Minutes Excerpt from the Press Release: SAN DIEGO, March 23, 2022 /PRNewswire/ — BioFluidica, a privately held biotechnology company, today announced they have been awarded a continuation grant from the Midwest Biomedical Accelerator Research Consortium (MBArC) on behalf of the National Institutes of Health Rapid Acceleration of…

Read More

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

03/30/2022

First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep’s development in large and rapidly growing pharmaceutical markets, including China, Hong Kong, Macau, Taiwan, Singapore, and South Korea Final cohort’s dosing regimen is equivalent to Oncolytics’ North American phase 2 trial in…

Read More

Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis

03/30/2022

Excerpt from the Press Release: SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 study of RT-102, an oral formulation of the human parathyroid hormone…

Read More

PHYLEX BIOSCIENCES PUBLISHES POSITIVE RESULTS OF PROTECTION STUDY AGAINST SARS-CoV-2 DELTA VARIANT WITH ITS SECOND-GENERATION mRNA VACCINE

03/29/2022

Excerpt from the Press Release: DEL MAR, Calif,, March 23, 2022 /PRNewswire/ — Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. The current vaccines offer limited protection over time against the omicron variant that is now dominating…

Read More

Thermo Fisher Scientific to Support National Program to Accelerate SARS-CoV-2 Variant Identification

03/29/2022

Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the world leader in serving science, today announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a new genotyping method for SARS-CoV-2 that could speed up the identification of variants as…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives